Anti-Coagulants - Moldova

Moldova

In Moldova, the revenue in the Anti-Coagulants market is estimated to reach US$1.95m by 2024.
It is projected to display an annual growth rate (CAGR 2024-2029) of 6.57%, leading to a market volume of US$2.68m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$16,740.00m in 2024.
Moldova's anti-coagulants market is experiencing a surge in demand due to an aging population and increasing prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Moldova has been showing steady growth in recent years.

Customer preferences: Patients in Moldova are increasingly opting for oral anticoagulants over traditional injectable ones due to their ease of use and lower risk of complications. There is also a growing demand for personalized medicine, with patients seeking tailored treatment plans based on their genetic makeup and other individual factors.

Trends in the market: The Anti-Coagulants market in Moldova is being driven by the increasing prevalence of cardiovascular diseases and blood disorders, as well as a growing elderly population. The market is also benefiting from the entry of new players and the introduction of innovative products, such as direct oral anticoagulants (DOACs) and biosimilars.

Local special circumstances: Moldova's healthcare system is still in the process of modernizing and faces significant challenges, such as limited funding and a shortage of medical personnel. This has led to disparities in access to healthcare services across the country, with patients in rural areas often having limited access to specialized care.

Underlying macroeconomic factors: Moldova's economy has been growing steadily in recent years, but remains one of the poorest in Europe. The country's healthcare system is heavily reliant on public funding, with out-of-pocket payments accounting for a significant portion of healthcare expenditures. This has led to a growing demand for affordable healthcare solutions, including generic drugs and biosimilars.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.